Contracts › W81XWH20C0137
W81XWH20C0137: This Award Is for the Delivery of a Cgmp Manufactured Product of Quantity and Quality That It Is Suitable and Appropriate for Use in Pivotal Clinical Studies to Demonstrate Efficacy Against Etec in Adults With the Goal of Fda Licensure.
Awarded to Scandinavian Biopharma Holding Ab by Defense Health Agency.
$40.6Mobligated
$51.7Mpotential value
30 September 2028current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | W81XWH20C0137 |
|---|---|
| Awardee | Scandinavian Biopharma Holding Ab |
| Awarding agency | Defense Health Agency |
| Awarding office | ARMY MED RES ACQ ACTIVITY |
| NAICS | 541714 Research and Development in Biotechnology (Except Nanobiotechnology) |
| PSC | Q517 Pharmacy Services |
| Offers received | 1 |
| Period of performance | 25 September 2020 to 30 September 2028 |
| Potential end | 30 September 2028 |
| Estimated recompete solicitation | ~Q2 2028 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 03 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541714 contracts · All expiring contracts · USASpending record